Tags

Type your tag names separated by a space and hit enter

Severe Acute Respiratory Syndrome Coronavirus 2-Specific Antibody Responses in Coronavirus Disease Patients.
Emerg Infect Dis. 2020 Jul; 26(7):1478-1488.EI

Abstract

A new coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has recently emerged to cause a human pandemic. Although molecular diagnostic tests were rapidly developed, serologic assays are still lacking, yet urgently needed. Validated serologic assays are needed for contact tracing, identifying the viral reservoir, and epidemiologic studies. We developed serologic assays for detection of SARS-CoV-2 neutralizing, spike protein-specific, and nucleocapsid-specific antibodies. Using serum samples from patients with PCR-confirmed SARS-CoV-2 infections, other coronaviruses, or other respiratory pathogenic infections, we validated and tested various antigens in different in-house and commercial ELISAs. We demonstrated that most PCR-confirmed SARS-CoV-2-infected persons seroconverted by 2 weeks after disease onset. We found that commercial S1 IgG or IgA ELISAs were of lower specificity, and sensitivity varied between the 2 assays; the IgA ELISA showed higher sensitivity. Overall, the validated assays described can be instrumental for detection of SARS-CoV-2-specific antibodies for diagnostic, seroepidemiologic, and vaccine evaluation studies.

Authors

No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

32267220

Citation

Okba, Nisreen M A., et al. "Severe Acute Respiratory Syndrome Coronavirus 2-Specific Antibody Responses in Coronavirus Disease Patients." Emerging Infectious Diseases, vol. 26, no. 7, 2020, pp. 1478-1488.
Okba NMA, Müller MA, Li W, et al. Severe Acute Respiratory Syndrome Coronavirus 2-Specific Antibody Responses in Coronavirus Disease Patients. Emerg Infect Dis. 2020;26(7):1478-1488.
Okba, N. M. A., Müller, M. A., Li, W., Wang, C., GeurtsvanKessel, C. H., Corman, V. M., Lamers, M. M., Sikkema, R. S., de Bruin, E., Chandler, F. D., Yazdanpanah, Y., Le Hingrat, Q., Descamps, D., Houhou-Fidouh, N., Reusken, C. B. E. M., Bosch, B. J., Drosten, C., Koopmans, M. P. G., & Haagmans, B. L. (2020). Severe Acute Respiratory Syndrome Coronavirus 2-Specific Antibody Responses in Coronavirus Disease Patients. Emerging Infectious Diseases, 26(7), 1478-1488. https://doi.org/10.3201/eid2607.200841
Okba NMA, et al. Severe Acute Respiratory Syndrome Coronavirus 2-Specific Antibody Responses in Coronavirus Disease Patients. Emerg Infect Dis. 2020;26(7):1478-1488. PubMed PMID: 32267220.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Severe Acute Respiratory Syndrome Coronavirus 2-Specific Antibody Responses in Coronavirus Disease Patients. AU - Okba,Nisreen M A, AU - Müller,Marcel A, AU - Li,Wentao, AU - Wang,Chunyan, AU - GeurtsvanKessel,Corine H, AU - Corman,Victor M, AU - Lamers,Mart M, AU - Sikkema,Reina S, AU - de Bruin,Erwin, AU - Chandler,Felicity D, AU - Yazdanpanah,Yazdan, AU - Le Hingrat,Quentin, AU - Descamps,Diane, AU - Houhou-Fidouh,Nadhira, AU - Reusken,Chantal B E M, AU - Bosch,Berend-Jan, AU - Drosten,Christian, AU - Koopmans,Marion P G, AU - Haagmans,Bart L, Y1 - 2020/06/21/ PY - 2020/4/9/pubmed PY - 2020/7/1/medline PY - 2020/4/9/entrez KW - COVID-19 KW - ELISA KW - HCoV KW - RBD KW - SARS-CoV-2 KW - Severe acute respiratory syndrome coronavirus 2 KW - antibodies KW - coronavirus KW - coronavirus disease 2019 KW - human coronavirus KW - neutralization KW - nucleocapsid protein KW - receptor-binding domain KW - respiratory infections KW - serologic analysis KW - spike protein KW - viruses KW - zoonoses SP - 1478 EP - 1488 JF - Emerging infectious diseases JO - Emerg Infect Dis VL - 26 IS - 7 N2 - A new coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has recently emerged to cause a human pandemic. Although molecular diagnostic tests were rapidly developed, serologic assays are still lacking, yet urgently needed. Validated serologic assays are needed for contact tracing, identifying the viral reservoir, and epidemiologic studies. We developed serologic assays for detection of SARS-CoV-2 neutralizing, spike protein-specific, and nucleocapsid-specific antibodies. Using serum samples from patients with PCR-confirmed SARS-CoV-2 infections, other coronaviruses, or other respiratory pathogenic infections, we validated and tested various antigens in different in-house and commercial ELISAs. We demonstrated that most PCR-confirmed SARS-CoV-2-infected persons seroconverted by 2 weeks after disease onset. We found that commercial S1 IgG or IgA ELISAs were of lower specificity, and sensitivity varied between the 2 assays; the IgA ELISA showed higher sensitivity. Overall, the validated assays described can be instrumental for detection of SARS-CoV-2-specific antibodies for diagnostic, seroepidemiologic, and vaccine evaluation studies. SN - 1080-6059 UR - https://www.unboundmedicine.com/medline/citation/32267220/full_citation L2 - https://doi.org/10.3201/eid2607.200841 DB - PRIME DP - Unbound Medicine ER -